MOLN - MOLECULAR PARTNERS AG

QQQ $ 422.58 $ -3.07 (-0.72 %)

DIA $ 378.81 $ 0.76 (0.2 %)

SPY $ 500.35 $ -1.63 (-0.32 %)

TLT $ 88.50 $ 0.65 (0.74 %)

GLD $ 213.80 $ 1.92 (0.91 %)

Previous Close

$ 3.87

Open

$ 3.86

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 3.76 - $ 4.03

52 Week Range

$ 3.32 - $ 7.32

Volume

4,917

Average Volume

Market Cap

140.69M

Beta (5Y Monthly)

$ 0.89

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Molecular Partners Announces Publication I...
04/29/2024 15:01:22

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while s...

Molecular Partners FY 2023 GAAP EPS $(2.13...
03/14/2024 20:11:22

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of ...

Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Molecular Partners AG Says Class Action Co...
03/01/2024 21:23:52

- Reuters

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
01/04/2024 13:05:58

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
01/03/2024 21:31:05

$molecular-partners-presented-initial-data-from-first-four-dosing-cohorts-of-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-2023-ash--meeting$

Molecular Partners Presented Initial Data ...
12/10/2023 17:51:47

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protei...

JP Morgan Maintains Neutral on Molecular P...
12/05/2023 15:48:29

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from ...

Molecular Partners To Present On DARPin On...
11/14/2023 07:06:38

Molecular Partners Presents Updated Data F...
11/03/2023 16:09:53

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironm...

$molecular-partners-to-present-initial-data-from-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-the-65th-ash-annual-meeting-and-exposition$

Molecular Partners To Present Initial Data...
11/02/2023 07:00:46

As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated....

Molecular Partners Announces Interim Manag...
10/26/2023 20:04:47

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be pre...

Molecular Partners To Present New Data On ...
09/13/2023 06:44:45

Stocks That Hit 52-Week Lows On Thursday
09/07/2023 17:55:53

On Thursday, 283 companies set new 52-week lows.

CORRECTION: Molecular Partners H1 EPS $(1....
08/24/2023 21:11:07

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earnings...

Molecular Partners H1 EPS $(1.05) Down Fro...
08/24/2023 20:18:26

Molecular Partners (NASDAQ: MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earning...

Molecular Partners To Present Data From On...
05/25/2023 21:04:15

Earnings Scheduled For March 9, 2023
03/09/2023 10:00:50

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

Reported Late Monday, Molecular Partners P...
12/13/2022 05:30:12

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri...

Molecular Partners Presents Interim Safety...
11/10/2022 06:40:57

First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities obs...